Last reviewed 2026-05-31 · How we verify

Octaplasma

Norwegian University of Science and Technology · Phase 2 active Small molecule ✓ Verified May 2026

Octaplasma is a Small molecule drug developed by Norwegian University of Science and Technology. It is currently in Phase 2 development.

Octaplasma is being studied as a potential treatment for Alzheimer's disease in a clinical trial. The trial, titled "Safety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease," is investigating the safety and efficacy of Octaplasma, ExPlas, and saline interventions.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Octaplasma
Sponsor	Norwegian University of Science and Technology
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Octaplasma CI brief — competitive landscape report
Octaplasma updates RSS · CI watch RSS
Norwegian University of Science and Technology portfolio CI

Frequently asked questions about Octaplasma

What is Octaplasma?

Octaplasma is a Small molecule drug developed by Norwegian University of Science and Technology.

Who makes Octaplasma?

Octaplasma is developed by Norwegian University of Science and Technology (see full Norwegian University of Science and Technology pipeline at /company/norwegian-university-of-science-and-technology).

What development phase is Octaplasma in?

Octaplasma is in Phase 2.

Manufacturer: Norwegian University of Science and Technology — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing